REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Longevity Foundation

Anti-Aging & Longevityintermediate

91

synergy

91
Share
Peptides

3

Avg Daily mcg

12,000

Level

intermediate

Added

May 17, 2026

Overview

The Longevity Foundation stack addresses three fundamental pillars of biological aging: telomere attrition, extracellular matrix degradation, and immune senescence. Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It activates telomerase — the enzyme that rebuilds telomere caps on chromosomes — in somatic cells. In Khavinson''s clinical studies, Epithalon administration to elderly patients was associated with reduced mortality, improved immune markers, and normalization of melatonin production from the pineal gland. It is administered in 10-day cycles, typically twice per year. GHK-Cu is a naturally occurring copper-binding tripeptide that functions as a master regulator of tissue remodeling. Beyond its surface-level skin benefits, GHK-Cu modulates the expression of over 4,000 genes — many involved in DNA repair, antioxidant production (SOD, glutathione), stem cell proliferation, and suppression of pro-inflammatory cytokines. Its concentration in human plasma drops from 200 ng/mL at age 20 to 80 ng/mL by age 60, correlating with visible aging and reduced regenerative capacity. Thymosin Alpha-1 addresses immunosenescence — the progressive decline of immune function with age that increases susceptibility to infections, cancer, and autoimmune conditions. By promoting T-cell maturation, dendritic cell activation, and natural killer cell function, Ta1 helps restore immune surveillance to more youthful levels. The three-peptide combination creates a comprehensive anti-aging protocol: Epithalon maintains chromosomal integrity, GHK-Cu restores tissue remodeling capacity and gene expression patterns, and Thymosin Alpha-1 rejuvenates immune competence. This represents a systems-biology approach to aging rather than targeting any single pathway.

Dosing Protocol

Epithalon

daily (10-day cycle)· subcutaneous

Read more about Epithalon →

10,000 mcg

per dose

GHK-Cu

Every day· subcutaneous

Read more about GHK-Cu →

500 mcg

per dose

Thymosin Alpha-1

2x/week· subcutaneous

Read more about Thymosin Alpha-1 →

1,500 mcg

per dose

Goals & Evidence

Telomere lengthImmune functionSkin qualityAnti-agingLongevity
Evidence tier:Human Data

Warnings

  • Epithalon is Cat 2. GHK-Cu and Thymosin Alpha-1 are Cat 1. Epithalon cycles: 10 days on, 6 months off.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.